- Motley Fool•5 hours ago
Investors should benefit from these biotechs' cholesterol drugs.
- Investopedia•9 hours ago
A survey of dermatologists expressed a positive opinion about Regeneron's eczema drug Dupixent.
- Zacks•12 hours ago
Amgen Inc. (AMGN) recently announced that its supplemental biologics license application (sBLA) for its leukemia immunotherapy, Blincyto, has been accepted for priority review by the FDA.
AMGN : Summary for Amgen Inc. - Yahoo Finance
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||164.12 x 100|
|Ask||168.50 x 200|
|Day's Range||163.21 - 164.80|
|52 Week Range||133.64 - 184.21|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||16.05|
|Dividend & Yield||4.60 (2.79%)|
|1y Target Est||N/A|